FIRST AMENDMENT TO SEVERANCE AGREEMENTSeverance Agreement • March 30th, 2012 • MAP Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This First Amendment to the Severance Agreement, dated February 1, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”).
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • March 30th, 2012 • MAP Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 (the “First Amendment”) to that certain Common Stock Purchase Agreement, dated November 11, 2009 (the “Agreement ”), by and between MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), is entered into as of 29 November, 2011 (the “First Amendment”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement.
FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 30th, 2012 • MAP Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This First Amendment to the Change in Control Agreement, dated February 1, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”).
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2012 • MAP Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This First Amendment to the Employment Agreement, dated February 6, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Thomas A. Armer, Ph.D (“Executive”).
FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 30th, 2012 • MAP Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This First Amendment to the Change in Control Agreement, dated February 6, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Thomas A. Armer, Ph.D (“Executive”).
